Table 1.

Status at 12 months among all patients with RA initiating a biologic DMARD 2010–2014 in Sweden

TNFiRTXTOCABA
%%RR%RR%RR
First bDMARD N=5568N=654N=202N=240
On drug68.487.81.34 (1.27–1.41)75.51.20 (1.09–1.31)77.71.15 (1.05–1.27)
On drug + EULAR Good resp.26.131.11.42 (1.19–1.69)53.12.03 (1.70–2.42)34.31.37 (1.10–1.72)
On drug + HAQ Improvement26.739.21.64 (1.40–1.93)45.01.54 (1.27–1.87)36.81.37 (1.09–1.71)
On drug + 28 Joint count = 020.322.41.13 (0.89–1.43)30.91.60 (1.21–2.11)22.81.26 (0.91–1.74)
Switch from TNFi N=1840N=408N=320N=256
On drug57.780.21.48 (1.37–1.60)73.01.36 (1.23–1.49)65.11.11 (0.98–1.26)
On drug + EULAR Good resp.11.424.01.87 (1.41–2.49)36.83.06 (2.37–3.94)14.61.16 (0.76–1.76)
On drug + HAQ Improvement16.634.31.85 (1.49–2.30)32.41.71 (1.33–2.19)20.41.10 (0.78–1.53)
On drug + 28 Joint count = 012.320.81.96 (1.43–2.70)19.92.12 (1.48–3.02)11.20.86 (0.48–1.52)
  • Adj. for region, sex, age, birth country, RF, dis. dur., HAQ, DAS28, co-medication, recent history of malignancy, infection, SSRI, and hospital days last 5 yrs.